Kelonia Therapeutics Employee Directory
Biotechnology ResearchMassachusetts, United States51-200 Employees
Kelonia Therapeutics, based in Boston, Massachusetts, is a biotechnology company focused on developing in vivo gene delivery therapies. Its platform uses a small set of potent vector-like particles to deliver genetic cargo directly to the intended tissue, aiming for precise, tissue-specific expression. The company is building a pipeline of genetic medicines intended to treat solid tumors, hematologic cancers, and other diseases. In January 2026, the FDA cleared the IND for KLN-1010 for relapsed and refractory multiple myeloma, marking a step toward clinical testing. Recent reporting notes Kelonia is pursuing in vivo CAR-T therapies, including a bispecific program targeting BCMA and CD19, alongside other undisclosed discovery-stage assets.